Please use this identifier to cite or link to this item:
Title: Third-generation antidepressants: do they offer advantages over the SSRIs?
Austin Authors: Olver, James S ;Burrows, Graham D;Norman, Trevor R 
Affiliation: Department of Psychiatry, University of Melbourne, Austin & Repatriation Medical Centre, West Heidelberg, Victoria, Australia
Issue Date: 2001
Publication information: Cns Drugs; 15(12): 941-54
Abstract: Third-generation antidepressants are a group of antidepressant agents of variable action, not confined to serotonin reuptake inhibition. These agents include venlafaxine, reboxetine, nefazodone and mirtazapine. Claims have been made for these agents in terms of improved efficacy, faster speed of onset of effect and greater safety in the treatment of depression compared with previous medications, such as the selective serotonin reuptake inhibitors (SSRIs). This article reviews the evidence for these improvements. Thirty active comparator studies were reviewed involving the third-generation antidepressant agents. While there were isolated reports of improvements over comparator agents for venlafaxine, reboxetine and mirtazepine, there were no convincing differences between third-generation agents and comparators in terms of overall efficacy, relapse prevention and speed of onset. The third-generation antidepressants were, however, of equivalent safety to SSRIs and maintained improvements in safety over first-generation agents.
Gov't Doc #: 11735614
Journal: CNS drugs
Type: Journal Article
Subjects: Antidepressive Agents.adverse effects.pharmacokinetics.therapeutic use
Clinical Trials as Topic
Depressive Disorder.drug therapy.prevention & control
Secondary Prevention
Serotonin Uptake Inhibitors.adverse effects.therapeutic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 24, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.